Physician profile
Reenu Malhotra
NPI 1295991198
$546.03
in general payments reported to CMS, 2019-2025
11 companies · $205 in 2025
The $205 reported for 2025 was more than what 79% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.37 · 2023: $33.00 · 2024: $293 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $531.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $112.75 | 2025 | Lynparza |
| Stemline Therapeutics INC. | $108.93 | 2024-2025 | Orserdu |
| Incyte Corporation | $71.02 | 2023-2025 | Monjuvi, Jakafi |
| Merck Sharp & Dohme LLC | $65.04 | 2024 | Keytruda, Lynparza |
| Mirati Therapeutics, INC. | $42.23 | 2024 | Krazati |
| Lilly USA, LLC | $36.16 | 2023-2024 | Verzenio, Retevmo, Jaypirca |
| Genzyme Corporation | $34.29 | 2024 | |
| Novartis Pharmaceuticals Corporation | $23.62 | 2025 | |
| Rigel Pharmaceuticals, INC. | $22.19 | 2024 | Rezlidhia, Tavalisse |
| Fresenius Kabi USA, LLC | $15.43 | 2024 | Stimufend |
| Intercept Pharmaceuticals, INC. | $14.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reenu Malhotra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.